The company hopes that its novel approach in Friedreich’s ataxia could still have legs, but other assets are further ahead.
The need for another pivotal trial of omaveloxolone in Friedreich's ataxia looks increasingly likely.
A look at biotech’s most valued upartnered assets sees new entries from Allakos and some Covid-19 projects.
Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.
Marinus celebrates pivotal trial success with ganaxolone, but a quick approval could depend on lenient regulators.
A Vantage analysis identifies 315 pivotal trials that, like Lexicon’s Scored and Soloist studies, risk never being completed.
Drug makers from across the globe feature in 2019’s list of best performing small biotech stocks, from Galapagos to Daiichi Sankyo to Arrowhead.